Medically reviewed on August 30, 2018.
Applies to the following strengths: 5 mg; 10 mg
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Diabetes Type 2
Initial dose: 5 mg orally once a day
-May increase to 10 mg orally once a day in patients tolerating therapy with lower dose and requiring additional glycemic control
Maximum dose: 10 mg/day
-Correct volume depletion prior to initiating therapy.
-If used in combination with insulin or an insulin secretagogue, a lower dose of insulin or the insulin secretagogue should be considered to reduce the risk of hypoglycemia.
Use: As an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.
Renal Dose Adjustments
Mild renal impairment (eGFR 60 mL/min/1.73 m2 or greater): No adjustment recommended
Moderate renal impairment (eGFR 30 to less than 60 mL/min/1.73 m2:): Initiation of therapy is not recommended
Severe renal impairment (eGFR is less than 30 mL/min/1.73 m2): Use is contraindicated
If during therapy, patients eGFR is persistently between 30 and less than 60 mL/min/1.73 m2; therapy should be discontinued
Liver Dose Adjustments
No adjustment recommended; however, for patients with severe hepatic impairment, use caution as the safety and efficacy has not been specifically studied
Safety and efficacy have not been established in patients younger than 18 years.
Consult WARNINGS section for additional precautions.
-Take orally in the morning, with or without food
Missed Dose: If a dose is missed, take it as soon as it is remembered, unless it is almost time for the next dose. If this is the case, skip the missed dose and take at the next regularly scheduled time; do not take 2 doses at the same time.
-Correct volume depletion prior to initiating treatment
-Not recommended for patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis
-Assess fluid status prior to initiation and monitor for signs and symptoms of volume depletion during therapy.
-Verify renal function at baseline, and monitor periodically during therapy.
-Monitor for signs and symptoms of acute kidney injury
-Monitor for LDL-C per standard of care.
-Evaluate for the presence of acidosis, including ketoacidosis in symptomatic patients, even if blood sugar is below 250 mg/dL.
-Read the US FDA-approved patient labeling (Medication Guide).
-This drug will cause the urine to test positive for glucose.
-Ensure adequate fluid intake to avoid adverse reactions related to volume depletion such as orthostatic hypotension.
-Seek medical advice during periods of stress as medical management of diabetes may change.
-Inform patients that genital mycotic infections, urinary tract infections, and hypersensitivity reactions may occur; patients should be instructed to contact their health care professional.
-Patients should be instructed to seek immediate medical attention for symptoms of tenderness, redness, or swelling of the genitals or the area from the genitals back to the rectum, especially if they have a fever and are feeling unwell.
-Patients experiencing symptoms of ketoacidosis such as difficulty breathing, nausea, vomiting, abdominal pain, confusion, and unusual fatigue, or sleepiness should be instructed to seek immediate medical attention.
-Patients should promptly report signs of macroscopic hematuria or other symptoms potentially related to bladder cancer.
-Patients should be instructed to seek medical attention promptly for signs and symptoms of acute kidney injury such as decreased urine, swelling in the legs or feet.
-Patients should be instructed on routine preventative foot care.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about dapagliflozin
- Dapagliflozin Side Effects
- During Pregnancy
- Drug Interactions
- En Español
- 104 Reviews
- Drug class: SGLT-2 inhibitors
- FDA Alerts (3)
Other brands: Farxiga